• Explore /
  • Poster
  • / Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced <em>EGFR</em>-mutated NSCLC.

Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC.

Abstract Poster

Authors

null

Pasi A. Janne

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA

Pasi A. Janne , Joseph Mostillo , Pomy Shrestha , Ruoyang Zhang , Pang-Dian Fan , Frédérique Cantero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT04676477

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3161)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3161

Abstract #

TPS3161

Poster Bd #

147b

Abstract Disclosures

Similar Posters

First Author: Conor Ernst Steuer

First Author: Helena Alexandra Yu

First Author: Nobuaki Mamesaya

First Author: Jonathan W. Goldman